Navigation Links
New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
Date:10/26/2007

Interim Results From Open-Label Follow-up Include Longer-term Safety

Findings

BOSTON, Oct. 26 /PRNewswire/ -- Adults with Attention Deficit Hyperactivity Disorder (ADHD) treated with CONCERTA(R) OROS(R) methylphenidate HCl Extended-release Tablets showed significant improvements in ADHD symptom management compared to adults taking placebo, according to study results presented today at a major psychiatric medical meeting.

"Pharmacological treatment of children and adolescents with ADHD is clearly established but relatively less is known about the treatment of adults with ADHD," notes the study's medical director, Sally Berry, M.D., PhD., of Johnson & Johnson Pharmaceutical Research and Development, LLC. "We're encouraged that the CONCERTA(R) findings presented today -- in which CONCERTA(R) significantly improved ADHD symptom management in adults -- can benefit the growing body of knowledge in this important therapeutic area." The data presented today are part of a Supplemental New Drug Application (sNDA) submitted in August 2007 to the Food and Drug Administration for use of CONCERTA(R) to treat adults with ADHD. CONCERTA(R) is already approved for the treatment of ADHD in children and adolescents ages six to 17.

About the Study

In the study presented today, efficacy was measured as a change in the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score. The results showed that CONCERTA(R) achieved a significantly superior reduction in AISRS total score compared to placebo (p=0.012) (mean change was -10.6 +/-1.09 for the CONCERTA(R) group vs. -6.8 +/-1.06 for the placebo group.

In addition, CONCERTA(R) was significantly superior compared to placebo for the key secondary efficacy variables: change in Clinical Global Impression-Improvement (CGI-I) rating (p=0.008); change in Conners' Adult ADHD Rating Scale-Self Report (CAARS-S:S) total score (p=0.029) and change in percent of subjects m
'/>"/>

SOURCE McNeil Pediatrics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 Egalet Corporation ... specialty pharmaceutical company focused on developing, manufacturing and ... of its previously announced underwritten public offering of ... public offering price of $11.25 per share. The ... 1,000,000 shares issued upon the exercise in full ...
(Date:7/31/2015)... Calif. , July 31, 2015  Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... appointment of Yujiro S. Hata to its ... experience in business and corporate development is a tremendous ... Ph.D., president and chief executive officer of Xencor. "Xencor ...
(Date:7/30/2015)... 2015 Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the lifesciences ... him on Edwards, board as we pursue our focused innovation ... CEO.  "Bob has provided a valuable perspective to our board, ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Halozyme Therapeutics,Inc. (Nasdaq: HALO ), a ... extracellular matrix, today announced,that enrollment is complete in ... of superficial bladder cancer. The Company began dosing,patients ... following the successful,completion of the initial Phase I ...
... Pharmacopeia,(Nasdaq: PCOP ), an innovator in ... today announced that Schering-Plough has,initiated a Phase 1 ... a,compound identified from the collaboration between the two ... treatment for respiratory,disease. Pharmacopeia will receive a $1 ...
Cached Medicine Technology:Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer 2Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer 3Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer 4Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate 2Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate 3Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate 4
(Date:7/31/2015)... ... July 31, 2015 , ... ... geared to patients and family members, medical professionals, and researchers, covering a variety ... The conference is a collaborative effort between the Mesothelioma Applied Research Foundation and ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... “HARMONY 2015”, one of the industry’s premier thought leadership symposiums, hosted by ... and 6. The event attracts over 250 “C”-level executives, administrators, directors of ...
(Date:7/31/2015)... ... 31, 2015 , ... The Mount Sinai Health System will work with Columbia ... of related, experimental treatments. The collaboration moves into the next phase with the recent ... of five state licenses to produce and dispense medical marijuana. , Mount Sinai ...
(Date:7/31/2015)... Miami, FL (PRWEB) , ... July 31, 2015 , ... ... penile enlargement techniques have also been advanced, upgraded, made more effective and less intrusive ... Loria of Loria Medical Penile Enlargement Center. Dr. Loria currently stands as the ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Heart Fit Clinic has ... angina until a heart rate of 150 beats versus 100 beats, this is a ... are able to give life back to patients with heart disease," he adds. People ...
Breaking Medicine News(10 mins):Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2
... who reported sleeping five hours or less per day when ... risk for substantial weight retention (11 pounds or more) at ... per day, according to a new study by Kaiser Permanente ... , The study, published in the November issue of ...
... Optimal Nutrition Inc. Chooses ,it, Girl PR to help promote ... ... 19 "it" Girl Public relations, one of,the leading Public ... addition of Optimal Nutrition Inc. (O.N.I.).,O.N.I. bestows a customized door-to-door ...
... Agency ... in Massachusetts -, WORCESTER, Mass., Nov. 19 The ... of auto, home and,business insurance in Massachusetts, announced today that ... auto product that will,deliver highly- competitive prices and innovative coverage ...
... Calif., Nov. 19 CorVel Corporation,(Nasdaq: CRVL ... shares,of its common stock under the stock repurchase ... In June 2006, the Board had approved a,1,500,000 ... 30,2007, the Company has repurchased 862,323 shares, with ...
... made, MINNEAPOLIS, Nov. 19 At its ... Directors of ClearWay Minnesota approved 11,grants for new ... Breathe Act,s,impact on young adults to interventions that ... Latino youth and African,immigrants. ClearWay Minnesota will award ...
... U.N. Environment Initiative to Northern New,Jersey, Planting ... MORRISTOWN, N.J., Nov. 18, 2007 Reaffirming,its ... Bayer,employee-volunteers and Girl Scouts from troops in ... grabbed their spades and planted 10,trees at ...
Cached Medicine News:Health News:Kaiser Permanente/Harvard Medical School study links lack of sleep to weight gain for new moms 2Health News:'it' Girl Public Relations Adds 'O.N.I.' New Organic Food Delivery Service to Its Lifestyle Division 2Health News:The Hanover Seeks to Cut Auto Rates by Up to 30 Percent or More; Shave Three Years Off State's Existing Six-Year Surcharge Period 2Health News:The Hanover Seeks to Cut Auto Rates by Up to 30 Percent or More; Shave Three Years Off State's Existing Six-Year Surcharge Period 3Health News:The Hanover Seeks to Cut Auto Rates by Up to 30 Percent or More; Shave Three Years Off State's Existing Six-Year Surcharge Period 4Health News:CorVel Corporation Announces Resumption of Stock Repurchases 2Health News:CorVel Corporation Announces Resumption of Stock Repurchases 3Health News:ClearWay Minnesota(SM) Board Approves $2.8 Million for Research Grants 2Health News:ClearWay Minnesota(SM) Board Approves $2.8 Million for Research Grants 3Health News:Bayer Awards Making Science Make Sense Grant to Girl Scouts 2Health News:Bayer Awards Making Science Make Sense Grant to Girl Scouts 3Health News:Bayer Awards Making Science Make Sense Grant to Girl Scouts 4Health News:Bayer Awards Making Science Make Sense Grant to Girl Scouts 5
... System RS 800 can sort different specimen ... sorting are not necessary anymore and all ... a very timesaving and economical way ... a Tube Type Identification via Cap Recognition ...
... detect sequences of the following viruses: ... and 3; influenza virus A and ... and B. Laboratories may use ... *Analyte Specific Reagents. Analytical ...
... Alert Detection Reagents provide molecular labs a ... assays. By using our MGB technology, combined ... is now able to provide molecular labs ... sequences of specific organisms or genetic mutations ...
... for the detection of two genetic ... mutation on the Factor V (Leiden) ... the Prothrombin gene. Laboratories may use ... *Analyte Specific Reagents. Analytical ...
Medicine Products: